Pharmaceuticals & Biotech
Clinical-stage pipelines, patent cliffs, biosimilar entry, pricing under negotiation.
MeridianConsensus
Decision-grade Market IntelligenceAny market · any geography
Industry coverage8 commissioned studies · $2.5T in aggregate coverage
Healthcare & Life Sciences.
From clinical-stage pipelines to hospital services. Our commissioned studies cut across the whole stack, pharmaceuticals, medical devices, diagnostics, life-sciences tools, and the health-system operators paying for all of it.
Our view
Thesis on Healthcare.
From clinical-stage pipelines to hospital services. Our commissioned studies cut across the whole stack, pharmaceuticals, medical devices, diagnostics, life-sciences tools, and the health-system operators paying for all of it.
Same methodology as every other Meridian verticalCommittee-reviewed before publication
What we research
Sub-sectors of Healthcare.
Every sub-sector below is commissionable as a standalone 30-chapter study, or scoped bespoke for investment-committee and diligence use.
Medical Devices
Device-cycle economics, FDA 510(k) flow, reimbursement, OEM vs specialist positioning.
Interactive · live
A working healthcare dashboard.
Every commissioned healthcare study ships as an interactive dashboard, size and trajectory, ranked share, regional cuts, segmentation. Hover every bar to see the underlying figure; every number is traceable to a named source.
Interactive dashboard · live
Pharma + medical devices · specimen
Overview
2025 size · 2026–2036 forecast · committee-signed
$2.50T
2019$2.57T
2020$2.64T
2021$2.71T
2022$2.79T
2023$2.86T
2024$2.94T
2025$3.67T forecast
2030$4.78T forecast
2036Revenue trajectory (historical 2020 – Q1 2026 · forecast 2026–2036)
Strategic themes · this quarter
What is moving in Healthcare.
The priorities our research committee is tracking across the sector this quarter. Sub-sectors describe structure; themes describe motion. Reports commissioned against these themes ship with the latest signal-read baked in.
IRA drug-price negotiation Round 2
2027 roster and pricing-impact modelling across exposed manufacturers.
Biosimilar entry calendar
Top-10 biologic patent cliff dates and biosimilar-manufacturer competitive positioning.
GLP-1 category expansion
Secondary indications (cardiovascular, sleep apnoea, addiction) and competitive response from portfolio players.
In the library
Commissioned studies.
Representative engagement
A recent Healthcare engagement.
Client identity is held under NDA; scope, methodology, and outcome are disclosed. Full engagement references available under mutual confidentiality.
Engagement
Healthcare Devices
Growth-stage private equity
−37.7%
Estimate variance reconciled
Scope
Independent reconciliation on a niche interventional-cardiology segment where peer estimates diverged by 37.7%. Provided variance analysis plus committee-reviewed point estimate.
Outcome
Identified a structural pricing mismatch; the fund re-priced its entry position before closing.
Who uses this research
Role-tested in Healthcare.
The four teams that most commonly commission healthcare research. Each role below maps to a specific use-case the commissioned study is scoped against, from diligence to annual planning.
Corporate Development · Pharma/Devices
Pipeline-asset, device-company, and digital-health acquisition diligence with clinical-risk framing.
Commission research
A healthcaremarket we haven’t yet covered?
Same methodology, same committee review, same written support. If you can describe the sub-sector, we can commission the study, accessible instantly on demand. Any geography, any boundary.
Adjacent coverage
Related verticals.
Intel Watchlist · from $89/mo
Track healthcare continuously — never miss a deal, exec move, or filing.
Senior Analyst Support ships an always-on intel feed: M&A 8-Ks, exec moves, regulatory dockets, and patent filings on healthcare. Email + Slack delivery. Cancel any time.